Psoriasis Vulgaris Clinical Trial
Official title:
Monocenter, Randomized, Blinded, Intraindividual Study Evaluating Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to Vitamin D
Patients will be screened up to 28 days before start of treatment. During the screening
visit, the purpose and procedures of the study will be explained to potential patients and
informed consent will be obtained.
At the baseline visit, all inclusion and exclusion criteria will be re-assessed. Eligible
patients will be randomized to treatment of the target area with either 30 minutes (group30)
or 15 minutes (group15) blue light at 600 milliwatt per square centimeter (mW/cm²).
Additionally, two study areas with similar clinical symptomatology will be determined and
will be randomized to blue light treated area and Daivonex (Vitamin D) treated area.
After randomization, patients will be trained on a demonstrator device (no actual treatment
to ensure investigator is blinded as to which group the patient is randomized to) as well as
the Daivonex cream. After patients have been instructed, treatment of the areas will be
applied daily (once per day, 5-7 times / week) at home for a treatment period of 12 weeks.
During those 12 weeks, patients will return to the study site for safety and effectiveness
assessments at week 2, 4, 8 and week 12. A phone call visit will be performed after one week
of treatment to check for any adverse events or problems in handling the device or the cream.
The visit at week 12 serves as end of treatment visit. The patients will be followed-up for
another 4 weeks. Treatment responses will be photo documented.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03669757 -
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis
|
Phase 1 | |
| Completed |
NCT03614078 -
A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT03584360 -
Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin
|
Phase 2 | |
| Recruiting |
NCT04994951 -
Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome.
|
Phase 2 | |
| Completed |
NCT02888236 -
LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris
|
Phase 2 | |
| Completed |
NCT02533973 -
Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population
|
Phase 4 | |
| Completed |
NCT02193815 -
A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
|
Phase 1 | |
| Completed |
NCT02004847 -
Blue Light for Treating Psoriasis Vulgaris
|
N/A | |
| Completed |
NCT01946386 -
A Vasoconstriction Study With LEO 90100
|
Phase 1 | |
| Recruiting |
NCT01443338 -
Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2
|
Phase 4 | |
| Completed |
NCT01188928 -
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
|
Phase 3 | |
| Completed |
NCT00764751 -
Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris
|
Phase 2 | |
| Completed |
NCT00236171 -
Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test
|
N/A | |
| Completed |
NCT04541329 -
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
|
Phase 4 | |
| Completed |
NCT06064084 -
Incretin Effect in Patients With Psoriasis and Controls
|
||
| Not yet recruiting |
NCT06398106 -
Proactive TDM Versus Standard Use of Biologics in Psoriasis
|
Phase 4 | |
| Recruiting |
NCT05390515 -
Psoriatic Immune Response to Tildrakizumab
|
Phase 4 | |
| Recruiting |
NCT05892640 -
Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis
|
N/A | |
| Recruiting |
NCT04950218 -
The Psoriasis Echo Study
|
||
| Completed |
NCT05184348 -
Plexin B2 Gene Expression and Polymorphisms in Psoriasis
|
Phase 1 |